1. Home
  2. SUZ vs HALO Comparison

SUZ vs HALO Comparison

Compare SUZ & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Suzano S.A.

SUZ

Suzano S.A.

HOLD

Current Price

$8.98

Market Cap

10.8B

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$130.18

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUZ
HALO
Founded
1924
1998
Country
Brazil
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8B
12.0B
IPO Year
2002
2001

Fundamental Metrics

Financial Performance
Metric
SUZ
HALO
Price
$8.98
$130.18
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$12.38
★ $108.78
AVG Volume (30 Days)
★ 3.0M
2.1M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 2.17%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 3.11
Revenue
N/A
★ $151,862,000.00
Revenue This Year
$8.90
$34.69
Revenue Next Year
$15.03
$11.65
P/E Ratio
★ $5.58
$41.39
Revenue Growth
N/A
N/A
52 Week Low
$7.56
$61.23
52 Week High
$11.54
$128.94

Technical Indicators

Market Signals
Indicator
SUZ
HALO
Relative Strength Index (RSI) 63.87 78.30
Support Level $8.09 $105.27
Resistance Level $9.17 N/A
Average True Range (ATR) 0.21 3.32
MACD 0.07 1.02
Stochastic Oscillator 93.20 99.87

Price Performance

Historical Comparison
SUZ
HALO

About SUZ Suzano S.A.

Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: